Financial Incentives for Abstinence Among Socioeconomically Disadvantaged Individuals in Smoking Cessation Treatment

Daria E. Kendzor, PhD, Michael S. Businelle, PhD, Insiya B. Poonawalla, MS, Erica L. Cuate, MPH, Anshula Kesh, MPH, Debra M. Rios, MS, Ping Ma, PhD, and David S. Balis, MD

Tobacco use is the leading cause of preventable death in the United States. Although the prevalence of smoking has declined to 18.1% among US adults, 27.9% of those living below the poverty threshold continue to smoke. Numerous studies have shown that socioeconomic disadvantage is associated with a reduced likelihood of smoking cessation, despite comparable numbers of quit attempts by individuals with higher socioeconomic status. Furthermore, abstinence rates among socially disadvantaged smokers enrolling in smoking cessation interventions are alarmingly low (e.g., point prevalence abstinence rates of 7%–13% and continuous abstinence rates of 2%–4% at 6-month follow-up). Factors, including exposure to stress or adversity (e.g., neighborhood problems, income instability), limited psychosocial resources (e.g., social support), greater nicotine dependence, greater negative affect, and poor adherence to smoking cessation treatments, may contribute to dismal smoking cessation outcomes and poor general health in socioeconomically disadvantaged populations.

Notably, contingency management (CM), or the tangible reinforcement of abstinence and other related outcomes, is an approach that has been effective for the promotion of abstinence among individuals participating in treatment substance abuse or dependence. The CM approach is also effective for promoting smoking abstinence in a variety of populations. Notably, Etter is evaluating the use of financial incentives for low-income smokers as part of an ongoing Internet-based smoking cessation program in Switzerland. However, the CM approach for smoking cessation has yet to be evaluated in mainstream clinic settings, such as safety net hospitals that serve economically disadvantaged smokers who are motivated to quit smoking. Recent survey research suggests that financial incentives for smoking cessation may be particularly appealing among individuals of low socioeconomic status. Thus, our purpose in this study was to test the effectiveness of offering small financial incentives to encourage short-term abstinence among economically disadvantaged smokers who enrolled in a tobacco cessation program at a safety net hospital.

METHODS

We recruited participants during their orientation visit to the Tobacco Cessation Clinic at the Dallas County, Texas, safety net hospital between August 2011 and April 2013. All patients newly enrolled in the tobacco cessation program heard a brief verbal description of the study from the study staff. We offered individuals the opportunity to be screened for eligibility to participate while they were waiting to meet with the clinic physician (or other prescribing provider) later that day. We obtained informed consent from all individuals before screening for eligibility. Individuals were eligible to participate in the study if they:

1. demonstrated higher than a sixth grade English literacy level,
2. were willing to quit smoking 7 days after their first visit,
3. were aged 18 years or older,
4. had an expired carbon monoxide (CO) level of 8 parts per million or greater,
5. were smoking 5 or more cigarettes per day, and
6. were able to attend all study visits.

Measures

Demographic characteristics information. We measured demographic and socioeconomic characteristics, including race/ethnicity,
gender, age, marital or partner status, years of smoking, educational attainment, insurance status, employment status, and household income.

Literacy. The Rapid Estimate of Adult Literacy in Medicine is an interviewer-administered checklist in which individuals are asked to read and pronounce 66 common medical terms. Individuals who pronounced 45 or more words correctly were considered to have greater than a sixth grade reading level.

Tobacco Use and Smoking Abstinence

We assessed tobacco use characteristics, including years of smoking, daily smoking rate, expired CO level (parts per million), and time to first cigarette upon waking in the morning. We calculated the Heaviness of Smoking Index based on the daily smoking rate and time to first cigarette at the baseline measurement. According to the Society of Research on Nicotine and Tobacco Subcommittee on Biochemical Verification, CO levels of 8 to 10 parts per million or greater suggest recent cigarette smoking with a sensitivity and specificity of approximately 90%. Thus, we defined abstinence on the quit date as a self-report of smoking abstinence since the previous evening at 10 P.M. (approximately 12 hours after quitting) in combination with an expired CO level of 10 parts per million or less. We defined 7-day point prevalence abstinence at weeks 1 to 4, and 12 weeks after the quit date as a self-report of abstinence from smoking over the past 7 days in combination with an expired CO level of less than 8 parts per million. We measured 30-day point prevalence abstinence at 12 weeks after the quit date, which we defined as self-reported abstinence over the past 30 days in combination with an expired CO level of less than 8 parts per million. Important advantages of point prevalence abstinence included the ability to consider individuals abstinent following delays in cessation or a return to abstinence after an initial lapse (for a review and discussion, see Velicer et al. and Hughes et al.). In our study, point prevalence abstinence was a particularly important outcome because financial incentives might have encouraged participants to return to abstinence following a lapse.

In cases where abstinence status could not be determined because of missing data, participants were considered nonabstinent. Complete smoking status data (i.e., self-reported smoking with or without biochemical verification or self-reported abstinence with biochemical verification) were available for 97.9% of participants on the scheduled quit date, 100% at 1 week after the quit date, 89.7% at 2 weeks after the quit date, 71.9% at 3 weeks after the quit date, 86.3% at 4 weeks after the quit date, and 74.2% at 12 weeks after the quit date. The proportion with incomplete smoking status data did not differ between treatment groups at any visit, although attendance was lower overall at 3 and 12 weeks after the quit date (i.e., more participants were considered nonabstinent because of nonattendance at these visits).

Participants were considered continuously abstinent at 4 and 12 weeks after the scheduled quit date if they reported that they had been abstinent since the quit date assessment (with a 12-hour grace period) and demonstrated expired CO levels of less than 8 parts per million at all attended visits. Participants who self-reported abstinence since the quit date, but had missing smoking status data (because of nonattendance) at some time points were considered continuously abstinent if they missed no more than 2 consecutive assessments and the data at the surrounding time points indicated abstinence. Note that 2 additional continuous abstinence variables were created that either allowed missing data at only 1 time point or did not allow any missing data. These variables were also evaluated as outcomes to confirm the robustness of findings related to continuous abstinence.

Procedure

A total of 222 individuals were assessed for study eligibility, and 69 did not meet inclusion criteria (Figure 1). Participants were excluded for the following reasons: expired CO level less than 8 parts per million (n = 29); less than a seventh grade reading level (n = 27); smoked fewer than 5 cigarettes per day or not currently smoking (n = 14); unable to read, speak, and understand English (n = 2); and uninterested or other (n = 5). Participants might have been excluded for more than 1 reason. Excluded individuals did not differ from study participants on gender, race/ethnicity, or age. However, those excluded from the study had significantly lower CO (10.62 vs 17.86 ppm; P < .001) and literacy levels (Rapid Estimate of Adult Literacy scores of 45.22 vs 60.99; P < .001) than study participants, and they smoked fewer cigarettes per day (before the quit date; 14.60 vs 17.49; P = .056), although the latter finding did not reach statistical significance.

Eligible participants (n = 153) were randomly assigned to usual care (UC) for smoking cessation (n = 75) or to UC plus financial incentives for smoking abstinence (CM; n = 78). However, 7 participants did not return after the baseline visit (i.e., did not participate in the intervention) and were therefore excluded from all analyses, leaving a final study sample of 146 participants (71 UC participants, 75 CM participants). Participants were followed weekly from 1 week before their scheduled quit date through 4 weeks after the quit date. After the first 18 participants were enrolled, a 12-week follow-up assessment was added to the protocol. Thus, a subsample of 128 participants was asked to complete the 12-week follow-up assessment (64 UC participants, 64 CM participants).

Usual care. The safety net hospital smoking cessation program offered all the recommended components of an intensive tobacco treatment intervention. Individuals interested in quitting smoking were referred (typically by treatment providers) to the tobacco cessation program. Individuals attended 1 initial clinic orientation and educational session provided by a respiratory therapist, followed by weekly group support sessions facilitated by social workers. Participants were seen individually by a physician or other prescribing provider on a weekly or as needed basis to receive pharmacotherapy and individual follow-up.

Contingency management. Participants assigned to CM received all components of UC as described previously. In addition, participants had the opportunity to earn weekly incentives in the form of gift cards, if they (1) self-reported abstinence during the past approximately 12 hours on the quit day (i.e., abstinence since 10 P.M. the previous evening), or self-reported abstinence during the past 7 days at each weekly visit from 1 week through 4 weeks after the quit date; and (2) provided an expired CO sample consistent with abstinence (i.e., CO < 10 ppm on the quit date, CO < 8 ppm at weeks 1–4
participants were compensated for this assessment with a $30 gift card.  

Statistical Analyses

We used SPSS version 20 (IBM, Armonk, NY) to generate descriptive statistics about the study sample. We conducted analysis of variance and $\chi^2$ analysis to determine whether there were differences in baseline characteristics between the intervention groups. We conducted unadjusted and adjusted logistic regression analyses to characterize the influence of CM relative to UC on point prevalence (quit date, and 1, 2, 3, 4, and 12 weeks after the quit date) and continuous abstinence (4 and 12 weeks after the quit date). Covariates in the adjusted analyses included pharmacological treatment, race/ethnicity, gender, age, years of education, and the number of cigarettes smoked per day before the quit date. All repeated measures analyses included treatment week (time) in the model. In addition, adjusted analyses included pharmacological treatment, race, gender, age, years of education, and the number of cigarettes smoked per day before quitting. We evaluated interaction effects by conducting unadjusted and adjusted analyses to determine whether the effect of intervention type on cessation outcomes over time varied by age, gender, race/ethnicity, education, cigarettes per day, pharmacological treatment, and week after quitting (time). We used STATA version 13.0 (StataCorp, College Station, TX) to conduct unadjusted and adjusted mixed effects logistic regression analyses to evaluate the overall effect of treatment on 7-day point prevalence abstinence over time (1–4 weeks after the quit date, n = 146; 1–4 and 12 weeks after the quit date, n = 128).

RESULTS

Participants (n = 146) were primarily Black, and more than half reported that they were uninsured, unemployed, and had a household income of less than $12,000 per year. No significant differences were found between the treatment groups on demographic, socioeconomic, or smoking characteristics (Table 1). Participants attended an average of 57.3% of the weekly support group sessions offered from 1 week before the quit date through 4 weeks after the quit date, and the percentage of sessions attended did not differ significantly by treatment group.

Pharmacological Treatment

Participants were most frequently prescribed nicotine replacement therapy (NRT; patch or gum, 50%; n = 73), followed by varenicline (34.9%; n = 51), and bupropion (9.6%; n = 14). The remaining 5.5% of participants were prescribed a combination of NRT and bupropion (n = 7), or their data were missing (n = 1). The $\chi^2$ analysis indicated that the intervention groups did not differ in the distribution of cessation medications prescribed. The proportion of participants prescribed each type of pharmacological treatment is presented by intervention group in Table 1. Abstinence rates at 4 and 12 weeks after quitting did not differ significantly by medication type. Seven-day point prevalence abstinence rates for those prescribed varenicline, NRT, and bupropion were 43.1%, 37.0%, and 36.8%, respectively. The $\chi^2$ analysis indicated that the intervention groups did not differ in the distribution of cessation medications prescribed. The proportion of participants prescribed each type of pharmacological treatment is presented by intervention group in Table 1. Abstinence rates at 4 and 12 weeks after quitting did not differ significantly by medication type. Seven-day point prevalence abstinence rates for those prescribed varenicline, NRT, and bupropion were 43.1%, 37.0%, and 36.8%, respectively.
TABLE 1—Participant Characteristics: Financial Incentives for Abstinence in Smoking Cessation Treatment; Dallas County, TX; 2011–2013

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Usual Care (n = 71), % or Mean (SD)</th>
<th>Usual Care + Financial Incentives (n = 75), % or Mean (SD)</th>
<th>All Participants (n = 146), % or Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>52.6 (7.4)</td>
<td>51.7 (7.3)</td>
<td>52.2 (7.3)</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>63.4</td>
<td>52.0</td>
<td>57.5</td>
</tr>
<tr>
<td>Race/ethnicity, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black/African American</td>
<td>57.7</td>
<td>66.7 has 12.3</td>
<td>62.3</td>
</tr>
<tr>
<td>White/Caucasian</td>
<td>31.0</td>
<td>25.3 hast 12.8</td>
<td>28.1</td>
</tr>
<tr>
<td>Latino/Hispanic</td>
<td>4.2</td>
<td>6.7</td>
<td>5.5</td>
</tr>
<tr>
<td>Multirace/other</td>
<td>7.0</td>
<td>1.3</td>
<td>4.1</td>
</tr>
<tr>
<td>Partner status (married/living with significant other)</td>
<td>31.0</td>
<td>32.0</td>
<td>31.5</td>
</tr>
<tr>
<td>Socioeconomic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education, y</td>
<td>12.1 (1.8)</td>
<td>12.0 (2.2)</td>
<td>12.0 (2.0)</td>
</tr>
<tr>
<td>Annual household income (&lt; $12 000)</td>
<td>52.1</td>
<td>58.7</td>
<td>55.5</td>
</tr>
<tr>
<td>Employment status (not employed)</td>
<td>81.7</td>
<td>89.3</td>
<td>85.6</td>
</tr>
<tr>
<td>Insurance status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uninsured</td>
<td>52.1</td>
<td>52.0</td>
<td>52.1</td>
</tr>
<tr>
<td>Medicaid/Medicare</td>
<td>39.4</td>
<td>40.0</td>
<td>39.7</td>
</tr>
<tr>
<td>Private/job/combination</td>
<td>8.5</td>
<td>8.0</td>
<td>8.2</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarettes smoked/d (before quit date)</td>
<td>17.0 (7.7)</td>
<td>18.0 (9.7)</td>
<td>17.5 (8.8)</td>
</tr>
<tr>
<td>Years of smoking</td>
<td>31.0 (6.6)</td>
<td>31.9 (8.2)</td>
<td>31.4 (8.4)</td>
</tr>
<tr>
<td>CO, ppm (baseline)</td>
<td>17.5 (6.7)</td>
<td>18.2 (8.6)</td>
<td>17.9 (7.7)</td>
</tr>
<tr>
<td>Smoke ≤ 5 minutes of waking</td>
<td>42.3</td>
<td>53.3</td>
<td>47.9</td>
</tr>
<tr>
<td>Heaviness of Smoking Index</td>
<td>3.1 (1.2)</td>
<td>3.4 (1.3)</td>
<td>3.3 (1.3)</td>
</tr>
<tr>
<td>Pharmacological treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicotine replacement therapy</td>
<td>50.7</td>
<td>49.3</td>
<td>50.0</td>
</tr>
<tr>
<td>Varenicline</td>
<td>32.4</td>
<td>37.4</td>
<td>34.9</td>
</tr>
<tr>
<td>Bupropion</td>
<td>11.3</td>
<td>8.0</td>
<td>9.6</td>
</tr>
<tr>
<td>Combination/missing</td>
<td>5.6</td>
<td>5.3</td>
<td>5.5</td>
</tr>
</tbody>
</table>

Note. CO = carbon monoxide. No significant differences between treatment groups were found on any variable included in the table.

35.7% at 4 weeks after quitting and 27.5%, 17.8%, and 21.4% at 12 weeks after quitting, respectively.

Smoking Cessation

Point prevalence abstinence. Unadjusted and adjusted logistic regression analysis indicated that CM participants were significantly more likely to achieve 7-day point prevalence abstinence than UC participants at 1 week after the quit date (46.7% [n = 35] vs 29.6% [n = 21] abstinence), 2 weeks after the quit date (40.0% [n = 30] vs 22.5% [n = 16] abstinence), 3 weeks after the quit date (40.0% [n = 30] vs 19.7% [n = 14] abstinence), and 4 weeks after the quit date (49.3% [n = 37] vs 25.4% [n = 18] abstinence; all P < 0.05). However, there were no between groups differences in point prevalence abstinence (approximately 12 hours) on the quit date. In the subsample (n = 128) that was offered the opportunity to complete the follow-up visit at 12 weeks after the quit date, CM participants were significantly more likely to achieve 7-day point prevalence abstinence than UC participants (52.8% [n = 21] vs 14.1% [n = 9] abstinence). CM participants were also more likely to achieve 30-day point prevalence abstinence at 12 weeks after the quit date (28.1% [n = 18] vs 10.9% [n = 7] abstinence). The odds of achieving point prevalence abstinence among those assigned to CM relative to UC are presented in Table 2. Point prevalence abstinence rates by intervention group are depicted in Figure 2.

Repeated point prevalence abstinence. Mixed-effects logistic regression analysis indicated that CM participants were significantly more likely to achieve 7-day point prevalence abstinence over time (1–4 weeks after the quit date and 1–12 weeks after the quit date) than those assigned to UC (Table 2).

Continuous abstinence. Logistic regression analysis indicated that CM participants were more likely to achieve continuous abstinence at 4 weeks after the quit date (25.3% [n = 19] vs 12.7% [n = 9] abstinent) than UC participants. In the subsample (n = 128) that was offered the opportunity to complete the follow-up visit at 12 weeks after the quit date, CM participants were also significantly more likely to achieve continuous abstinence at 12 weeks after the quit date than UC participants (20.3% [n = 13] vs 7.8% [n = 5] abstinent). CM participants were more likely to achieve continuous abstinence at 4 and 12 weeks after the quit date, even when more conservative definitions of continuous abstinence were used (see descriptions in the Measures section; all P < 0.05; detailed results available upon request). The odds of achieving continuous abstinence in CM relative to UC are presented in Table 2.

Treatment Interactions

Age, race/ethnicity, education, cigarettes per day, pharmacological treatment, and weeks following the scheduled quit date (time) did not interact with the treatment group to predict repeated point prevalence abstinence. However, the treatment group interacted significantly with gender to predict 7-day point prevalence abstinence through 4 weeks after the quit date (n = 146 in unadjusted (P = .006) and adjusted analysis (P = .01). Similarly, the treatment group interacted significantly with gender to predict 7-day point prevalence abstinence through 12 weeks after the quit date (n = 128 in unadjusted (P = .028) and adjusted analysis (P = .03). Specifically, women assigned to the CM group had the highest abstinence rates over the first...
and 12 weeks after the quit date, whereas women assigned to UC had the lowest abstinence rates. Conversely, abstinence rates were more similar among men in the CM and UC groups (Figure 2).

The average amount of incentives earned for abstinence among CM participants between the quit date and 4 weeks after the quit date was $63.40 (SD = $51.67) of a possible $150.

**DISCUSSION**

We demonstrated the short-term effectiveness of offering small financial incentives for biochemically verified abstinence as an adjunct to an existing smoking cessation program provided at an urban safety net hospital. Adjunctive financial incentives doubled abstinence rates relative to UC in an extremely socioeconomically disadvantaged and primarily Black sample. The positive effect of financial incentives on abstinence rates remained 8 weeks after the incentives were discontinued, and findings indicated that financial incentives might work particularly well for improving abstinence rates among socioeconomically disadvantaged women. Thus, small financial incentives for smoking cessation might be an affordable, practical, and effective means of increasing cessation rates and reducing tobacco-related disease in the safety net hospital setting.

Numerous studies showed that offering financial incentives for smoking cessation was an effective strategy for promoting smoking abstinence.\(^{19-31}\) We added to previous research by demonstrating that providing adjunctive short-term financial incentives is also an effective approach to smoking cessation in the safety net hospital setting. Furthermore, the CM approach used in our study was effective at increasing abstinence rates in an extremely disadvantaged population who would otherwise be less likely to quit smoking (for a review, see Hiscock et al.\(^{14}\)). Lower rates of abstinence in UC were consistent with findings from other cessation studies in socioeconomically disadvantaged populations.\(^{8,9,11-13,31}\) Notably, the amount of incentives offered in the our study was low ($20–$40 per visit; $150 possible over 8 weeks).

**TABLE 2—Odds of Abstinence Among Those Who Received Financial Incentives Relative to Usual Care: Financial Incentives for Abstinence in Smoking Cessation Treatment; Dallas County, TX; 2011–2013**

<table>
<thead>
<tr>
<th></th>
<th>4 Weeks Postquit (n = 146)</th>
<th>12 Weeks Postquit (n = 128)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted OR (95% CI)</td>
<td>Adjusted OR (95% CI)</td>
</tr>
<tr>
<td></td>
<td>Unadjusted OR (95% CI)</td>
<td>Adjusted OR (95% CI)</td>
</tr>
<tr>
<td>7-d point prevalence abstinence</td>
<td>2.87** (1.42, 5.77)</td>
<td>3.40*** (1.61, 7.16)</td>
</tr>
<tr>
<td>30-d point prevalence abstinence</td>
<td>. . . . . .</td>
<td>. . . . . .</td>
</tr>
<tr>
<td>Repeated point prevalence abstinence(^a)</td>
<td>5.40*** (1.92, 15.14)</td>
<td>5.36*** (1.93, 14.90)</td>
</tr>
<tr>
<td>Continuous abstinence</td>
<td>2.34 (0.98, 5.59)</td>
<td>2.59* (1.04, 6.42)</td>
</tr>
</tbody>
</table>

Note. Values in the table reflect the odds of achieving abstinence for those assigned to the adjunctive financial incentives intervention relative to usual care. Pharmacological treatment, race, gender, age, years of education, and before quitting cigarettes smoked per day were included in the adjusted models.

\(^a\)Repeated measures analyses included 7-day point prevalence abstinence at 1, 2, 3, 4, and 12 weeks after the quit date as the outcomes. Treatment week (time) was additionally included in both the adjusted and unadjusted analyses.

\(*P < .05; **P < .01; ***P = .001.\)

Note. CM = contingency management; UC = usual care. A subsample of 128 participants was asked to complete the follow-up visit 12 weeks after the quit date. Values reflect 7-day point prevalence abstinence at all visits except for the quit date, which reflects approximately 12 hours of abstinence. Intervention group differences in abstinence rates were significant at all visits except for the quit date in both unadjusted and adjusted analyses (all \(P_s < .05\)).

**FIGURE 2—Biochemically verified point prevalence abstinence by treatment group and gender: Financial Incentives for Abstinence in Smoking Cessation Treatment; Dallas County, TX; 2011–2013.**
Researchers suggested that daily monitoring of smoking status might be required to accurately verify smoking status within CM interventions. However, daily monitoring is impractical for hospital programs and patients. At 4 weeks after the quit date, we found that only 3% of study participants (n = 4) provided a self-report of abstinence in combination with an expired CO level that suggested nonabstinence. It appears that most people were honest about their smoking status or were unaware of the limitations of measuring expired CO. Moreover, although the half-life of CO is up to 8 hours depending on a variety of factors, studies showed that expired CO is a valid indicator of smoking status and cessation outcomes, and compares favorably with cotinine and other biochemical measures with longer detection windows. Unfortunately, smoking status could not be validated with cotinine measurement in our study because half of study participants were prescribed NRT. Notably, the CM approach in our study was associated with higher point prevalence abstinence rates even when a more conservative CO level of less than 4 parts per million was used as verification of self-reported abstinence (results available upon request). As such, we believe that self-reports of abstinence combined with CO levels suggestive of recent abstinence provided a reasonably accurate, immediate, and practical measure of abstinence that is already available in many clinic settings.

Study Limitations
Our study had strengths and limitations. We were the first to examine the effectiveness of using small, weekly financial incentives to promote smoking abstinence as part of a safety net hospital smoking cessation program. In addition, the intervention was evaluated within a primarily Black and extremely socioeconomically disadvantaged population that had a reduced likelihood of smoking cessation. A major limitation of this study was the lack of long-term follow-up, although early abstinence and more time abstinent following a quit attempt were associated with a greater likelihood of achieving long-term smoking abstinence. Thus, the CM approach utilized in our study holds promise for promoting longer term abstinence in socioeconomically disadvantaged populations.

Conclusions
Future research should focus on characterizing the long-term influence of financial incentives on cessation, and refining the CM approach for use within socioeconomically disadvantaged populations. Research is needed to determine the optimal value of incentives and length of time that incentives should be offered. Other types of incentives should also be explored, such as lotteries in which abstinent participants are represented in drawings for prizes rather than receiving an individual payment. Finally, future research should focus on evaluating and implementing the CM approach for smoking cessation among socioeconomically disadvantaged patients in other real-world settings.

In summary, we demonstrated that offering adjunctive financial incentives approximately doubled short-term abstinence rates relative to UC among safety net hospital patients motivated to quit smoking. The positive effect of the incentives on cessation outcomes remained at 12 weeks after the quit date, which was 8 weeks after the incentives were discontinued. Thus, including small financial incentives as part of standard smoking cessation programs might help to improve cessation rates among socioeconomically disadvantaged smokers, and particularly among women, in the safety net hospital setting. In turn, increased rates of smoking cessation might reduce tobacco-related disease, tobacco-related hospital expenditures, and socioeconomic and racial/ethnic disparities in health.

About the Authors
Darla E. Kendzor, Michael S. Businelle, Instiga B. Poonawalla, Erica L. Caste, Anshula Kesh, and Debra M. Businelle are with the University of Texas Health Science Center. School of Public Health, Dallas. Peng Ma is with the Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas. Davis S. Balis is with the Department of General Internal Medicine, University of Texas Southwestern Medical Center, Dallas.

Correspondence should be sent to Darla E. Kendzor, PhD, The University of Texas Health Science Center, School
of Public Health, 6011 Harry Hines Boulevard, Dallas, TX 75390-9128, e-mail: Darla.Kendzor@UTSouthwestern.edu. Reprints can be ordered at http://www.ajpnh.org by clicking the “Reprints” link.

This article was accepted May 12, 2014.

Contributors
D. E. Kendzor contributed to study conceptualization and data analysis, and was the primary author of the article. M. S. Businelle contributed to study conceptualization and article preparation. I. B. Poornawalla, E. L. Cuate, A. Kesh, D. M. Rios, and D. S. Bals contributed to article preparation. P. Ma contributed to data analysis and article preparation.

Acknowledgments
Funding for this research was provided by the University of Texas Southwestern Medical Center, School of Public Health. Data analysis and article preparation were additionally supported by American Cancer Society grants MBSGT-10-104-01-CPHPS (to D. E. K) and MBSGT-12-114-01-CPPB (to M. S. B).

Human Participant Protection
This research was approved by the institutional review boards of the University of Texas Southwestern Medical Center (STU 0422011-098) and the University of Texas Health Science Center (HSC-SPH-11-0269). Informed consent was obtained from all participants.

References


